Pfizer buys Array BioPharma in $11.4bn deal
In an effort to expand its cancer offerings with targeted therapies, Pfizer Inc. is paying $11.4bn in cash ($48 per share; a 66% premium) to acquire Array BioPharma Inc.
- Drug Discovery Tools
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com